Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC)
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders
BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders
Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript
Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline
Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know
Should You Buy Blueprint Medicines (BPMC) After Golden Cross?
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?
Blueprint Medicines price target lowered by $11 at Wedbush, here's why
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?